Cancer Pain Management
Introduction to Oral Morphine Sulfate
- Oral morphine sulfate controlled-release (MS Contin) is the first-line strong opioid of choice for patients with moderate to severe cancer pain that cannot be adequately controlled with non-opioid analgesics or weak opioids, as recommended by the British medical community and supported by the European Society for Medical Oncology and the National Comprehensive Cancer Network 1, 2, 3, 4, 5
Dose Adjustment and Conversion
- When converting from parenteral morphine to oral MS Contin, the relative potency ratio is between 1:2 and 1:3, and when converting from other opioids, use established equianalgesic dose ratios and start at the lower end of the equianalgesic dose range, providing rescue doses as needed, according to the British medical community and the National Comprehensive Cancer Network 6, 2, 3, 7
- The initial dose for opioid-naïve patients can be long-acting morphine at 15-30 mg orally every 12 hours or oxycodone at 10-20 mg orally every 12 hours, with careful titration based on pain control and side effects, as recommended by the National Comprehensive Cancer Network 7, 8
- Increase dose by 10-20% for inadequate pain control, and provide breakthrough doses equivalent to approximately 10-15% of the total daily dose, according to the National Comprehensive Cancer Network and Annals of Oncology 7, 9
- Opioid-tolerant patients are defined as those taking at least 30 mg oral oxycodone/day (or equivalent) for one week or longer, according to the National Comprehensive Cancer Network 7
- The following conversion factors can be used to calculate morphine milligram equivalents (MME):
| Opioid | Conversion Factor |
|---|---|
| Oxycodone | 1.5 |
Management of Side Effects
- Constipation should always be anticipated and managed prophylactically with a stimulant laxative with or without a stool softener, as recommended by the British medical community and the National Comprehensive Cancer Network 1, 7
- Monitor for respiratory depression, excessive sedation, nausea, and vomiting, and consider concomitant antiemetics, as suggested by the BMJ and the European Society for Medical Oncology 11, 5
- Patients should be monitored closely for respiratory depression, especially within the first 24-72 hours of therapy and following dose increases, and efficacy and side effects should be assessed every 60 minutes for oral medications, according to the National Comprehensive Cancer Network 7
- If side effects become intolerable, switching to another opioid may allow for adequate analgesia with fewer adverse effects, as suggested by the National Comprehensive Cancer Network and the European Society for Medical Oncology 7, 12, 13
Discontinuation of Treatment
- Never stop MS Contin treatment abruptly, and when discontinuing, reduce the dose in steps of 30-50% over about a week, as recommended by the British medical community and the National Comprehensive Cancer Network 1, 2
- The goal of pain management in cancer patients is to provide adequate analgesia with minimal side effects, as recommended by the National Comprehensive Cancer Network and the European Society for Medical Oncology 2, 3, 4, 5
Special Considerations
- Alternative opioids like buprenorphine or fentanyl may be preferable in moderate to severe renal dysfunction, as suggested by the European Society for Medical Oncology 5
- The National Comprehensive Cancer Network recommends using morphine with caution in patients with renal impairment due to potential accumulation of renally cleared metabolites that may cause neurologic toxicity, and consider lower initial doses and more gradual titration in elderly patients or those with renal impairment, as suggested by Annals of Oncology and the European Society for Medical Oncology 2, 9, 5
- Elderly patients may require lower initial doses due to altered pharmacokinetics, and for patients with severe pain requiring urgent relief, consider parenteral opioids initially, according to Annals of Oncology and the European Society for Medical Oncology 14, 12
- The CDC guidelines suggest that clinicians should use the lowest effective dose, with careful consideration of the risk-benefit ratio as doses increase, and pause to reassess benefits and risks before increasing total opioid dosage to ≥50 MME/day, and additional dosage increases beyond 50 MME/day are progressively more likely to yield diminishing returns in benefits relative to risks, according to the CDC guidelines 10
- Tolerance and physical dependence are not significant problems in patients with cancer pain when properly managed, according to the British Journal of Cancer, and unlike some opioids, pure agonists like oxycodone do not have a ceiling effect for analgesia, as stated by the British Journal of Cancer 1